See the DrugPatentWatch profile for cosentyx

Before starting Cosentyx (secukinumab), it is important to discuss any heart-related concerns with a healthcare provider. This is because Cosentyx, like other medications, can have potential effects on various parts of the body, including the cardiovascular system.

According to the Cosentyx prescribing information, there is a risk of hypersensitivity reactions, including angioedema and urticaria [1]. Angioedema is a type of swelling that can occur in the face, lips, tongue, or throat, which can potentially be life-threatening if it affects the airways [1]. Urticaria, also known as hives, is a skin reaction that can be associated with angioedema [1].

In addition, there have been reports of ischemic events, such as myocardial infarction (heart attack) and stroke, in patients taking Cosentyx [1]. However, it is important to note that the data on these events is limited, and it is not clear if Cosentyx is the cause of these events [1].

Therefore, it is crucial for individuals with a history of heart-related concerns, such as heart disease, high blood pressure, or stroke, to discuss these conditions with their healthcare provider before starting Cosentyx [1]. This will help the healthcare provider determine if Cosentyx is appropriate for the individual's specific situation.

It is also important to note that drug interactions can occur with Cosentyx, including with medications that affect the cardiovascular system [1]. Therefore, it is essential to provide a complete list of all medications, including over-the-counter products and supplements, to the healthcare provider [1].

In summary, individuals with heart-related concerns should discuss these conditions with their healthcare provider before starting Cosentyx. This will help ensure that Cosentyx is appropriate for the individual's specific situation and that any potential drug interactions are identified and managed.

Sources:
[1] Cosentyx (secukinumab) prescribing information. Novartis Pharmaceuticals Corporation. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>. Accessed March 23, 2023.

Additional sources:
DrugPatentWatch.com. Secukinumab (Cosentyx) Patent Expiration & Generics. <https://www.drugpatentwatch.com/drugs/secukinumab>. Accessed March 23, 2023.
Mayo Clinic. Angioedema. <https://www.mayoclinic.org/diseases-conditions/angioedema/symptoms-causes/syc-20371261>. Accessed March 23, 2023.
American Heart Association. What is Cardiovascular Disease? <https://www.heart.org/en/health-topics/consumer-healthcare/what-is-cardiovascular-disease>. Accessed March 23, 2023.